C-Jun NH_2-Terminal Kinase Contributes to Dexmedetomidine-Induced Contraction in Isolated Rat Aortic Smooth Muscle
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Dexmedetomidine, a full agonist of α_2B-adrenoceptors, is used for analgesia and sedation in the intensive care units. Dexmedetomidine produces an initial transient hypertension due to the activation of post-junctional α_2B-adrenoceptors on vascular smooth muscle cells (SMCs). The aims of this in vitro study were to identify mitogen-activated protein kinase (MAPK) isoforms that are primarily involved in full, α_2B-adrenoceptor agonist, dexmedetomidine-induced contraction of isolated rat aortic SMCs. Materials and Methods: Rat thoracic aortic rings without endothelium were isolated and suspended for isometric tension recording. Cumulative dexmedetomidine (10-9 to 10-6 M) dose-response curves were generated in the presence or absence of extracellular signal-regulated kinase (ERK) inhibitor PD 98059, p38 MAPK inhibitor SB 203580, c-Jun NH_2-terminal kinase (JNK) inhibitor SP 600125, L-type calcium channel blocker (verapamil and nifedipine), and α_2-adrenoceptor inhibitor atipamezole. Dexmedetomidine-induced phosphorylation of ERK, JNK, and p38 MAPK in rat aortic SMCs was detected using Western blotting. Results: SP 600125 (10^-6 to 10^-5 M) attenuated dexmedetomidine-evoked contraction in a concentration-dependent manner, whereas PD 98059 had no effect on dexmedetomidine-induced contraction. SB 203580 (10^-5 M) attenuated dexmedetomidine-induced contraction. Dexmedetomidine-evoked contractions were both abolished by atipamezole and attenuated by verapamil and nifedipine. Dexmedetomidine induced phosphorylation of JNK and p38 MAPK in rat aortic SMCs, but did not induce phosphorylation of ERK. Conclusion: Dexmedetomidine-induced contraction involves a JNK- and p38 MAPK-mediated pathway downstream of α_2-adrenoceptor stimulation in rat aortic SMCs. In addition, dexmedetomidine-induced contractions are primarily dependent on calcium influx via L-type calcium channels.
Abstract
Purpose: Dexmedetomidine, a full agonist of α_2B-adrenoceptors, is used for analgesia and sedation in the intensive care units. Dexmedetomidine produces an initial transient hypertension due to the activation of post-junctional α_2B-adrenoceptors on vascular smooth muscle cells (SMCs). The aims of this in vitro study were to identify mitogen-activated protein kinase (MAPK) isoforms that are primarily involved in full, α_2B-adrenoceptor agonist, dexmedetomidine-induced contraction of isolated rat aortic SMCs. Materials and Methods: Rat thoracic aortic rings without endothelium were isolated and suspended for isometric tension recording. Cumulative dexmedetomidine (10-9 to 10-6 M) dose-response curves were generated in the presence or absence of extracellular signal-regulated kinase (ERK) inhibitor PD 98059, p38 MAPK inhibitor SB 203580, c-Jun NH_2-terminal kinase (JNK) inhibitor SP 600125, L-type calcium channel blocker (verapamil and nifedipine), and α_2-adrenoceptor inhibitor atipamezole. Dexmedetomidine-induced phosphorylation of ERK, JNK, and p38 MAPK in rat aortic SMCs was detected using Western blotting. Results: SP 600125 (10^-6 to 10^-5 M) attenuated dexmedetomidine-evoked contraction in a concentration-dependent manner, whereas PD 98059 had no effect on dexmedetomidine-induced contraction. SB 203580 (10^-5 M) attenuated dexmedetomidine-induced contraction. Dexmedetomidine-evoked contractions were both abolished by atipamezole and attenuated by verapamil and nifedipine. Dexmedetomidine induced phosphorylation of JNK and p38 MAPK in rat aortic SMCs, but did not induce phosphorylation of ERK. Conclusion: Dexmedetomidine-induced contraction involves a JNK- and p38 MAPK-mediated pathway downstream of α_2-adrenoceptor stimulation in rat aortic SMCs. In addition, dexmedetomidine-induced contractions are primarily dependent on calcium influx via L-type calcium channels.
참고문헌 (39)
- Virtanen R, "Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist", Eur J Pharmacol, 150, pp.9~14 (1988)
- GTPgammaS binding by recombinant alpha 2-adrenoceptors, "Eur J Pharmacol", 1998, 375~379
- Schmeling WT, "The effects of the stereoisomers of the alpha 2-adrenergic agonist medetomidine on systemic and coronary hemodynamics in conscious dogs", Anesthesiology, 75, pp.499~511 (1991)
- Bloor BC, "Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes", Anesthesiology, 77, pp.1134~1142 (1992)
- Hall JE, "Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions", Anesth Analg, 90, pp.699~705 (2000)
- Lawrence CJ, "Hemodynamic and coronary vascular effects of dexmedetomidine in the anesthetized goat", Acta Anaesthesiol Scand, 41, pp.830~836 (1997)
- Jalonen J, "Effects of dexmedetomidine on coronary hemodynamics and myocardial oxygen balance", J cardiothorac Vasc Anesth, 9, pp.519~524 (1995)
- Flacke WE, "Effects of dexmedetomidine on systemic and coronary hemodynamics in the anesthetized dog", J Cardiothorac Vasc Anesth, 7, pp.41~49 (1993)
- Guimaräes S, "Vascular adrenoceptors: an update", Pharmacol Rev, 53, pp.319~356 (2001)
- Mizobe T, "Adrenergic receptor and knockout mouse: 2). Alpha adrenergic receptor knockout mouse", Masui, 50, pp.12~19 (2001)
- Akata T, "General anesthetics and vascular smooth muscle: direct actions of general anesthetics on cellular mechanisms regulating vascular tone", Anesthesiology, 106, pp.365~391 (2007)
- Abdel-Latif AA, "Cross talk between cyclic nucleotides and polyphosphoinositide hydrolysis, protein kinases, and contraction in smooth muscle", Exp Biol Med (Maywood), 226, pp.153~163 (2001)
- Khan TA, "Mitogen-activated protein kinase pathways and cardiac surgery", J Thorac Cardiovasc Surg, 127, pp.806~811 (2004)
- Kim B, "p38 mitogen-activated protein kinase contributes to the diminished aortic contraction by endothelin-1 in DOCA-salt hypertensive rats", HYPERTENSION, 43, pp.1086~1091 (2004), LIPPINCOTT WILLIAMS & WILKINS
- Lee YR, "C-Jun N-terminal kinase contributes to norepinephrine-induced contraction through phosphorylation of caldesmon in rat aortic smooth muscle", J Pharmacol Sci, 100, pp.119~125 (2006)
- Carter RW, "Tyrosine kinases regulate intracellular calcium during alpha (2)-adrenergic contraction in rat aorta", Am J Physiol Heart Circ Physiol, 283, pp.H1673~H1680 (2002)
- Roberts RE, "Role of the extracellular signal-regulated kinase (Erk) signal transduction cascade in alpha (2) adrenoceptor-mediated vasoconstriction in porcine palmar lateral vein", Br J Pharmacol, 133, pp.859~866 (2001)
- Choi YS, "The Direct Effect of Levobupivacaine in Isolated Rat Aorta Involves Lipoxygenase Pathway Activation and Endothelial Nitric Oxide Release", ANESTHESIA AND ANALGESIA, 110(2), pp.341~349 (2010), LIPPINCOTT WILLIAMS WILKINS
- Sung HJ, "Direct effect of ropivacaine involves lipoxygenase pathway activation in rat aortic smooth muscle", CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 56(4), pp.298~306 (2009), CANADIAN ANESTHESIOLOGISTS SOC
- Klegeris A, "Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells", FASEB J, 20, pp.2000~2008 (2006)
- Park MK, "The obligatory role of COX-2 expression for induction of HO-1 in ischemic preconditioned rat brain", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 377(4), pp.1191~1194 (2008), ACADEMIC PRESS INC ELSEVIER SCIENCE
- 곽경화, "Emergence agitation", delirium: we still don’t know, 2010, pp.59(2), 73~74[DOI]
- Dessy C, "A role for MAP kinase in differentiated smooth muscle contraction evoked by alpha-adrenoceptor stimulation", Am J Physiol, 275, pp.C1081~C1086 (1998)
- Touyz RM, "Mitogen-activated protein", extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells, 1999, pp.84, 505~515
- Watts SW, "Activation of Erk mitogen-activated protein kinase proteins by vascular serotonin receptors", J Cardiovasc Pharmacol, 38, pp.539~551 (2001)
- Civantos Calzada B, "Alpha-adrenoceptor subtypes", Pharmacol Res, 44, pp.195~208 (2001)
- Yildiz O, "Dexmedetomidine produces dual alpha 2-adrenergic agonist and alpha 1-adrenergic antagonist actions on human isolated internal mammary artery", J Cardiothorac Vasc Anesth, 21, pp.696~700 (2007)
- Bain J, "The selectivity of protein kinase inhibitors: a further update", Biochem J, 408, pp.297~315 (2007)
- Molin JC, "Clonidine induces rat aorta relaxation by nitric oxide-dependent and -independent mechanisms", Vascul Pharmacol, 42, pp.1~6 (2004)
- Hamasaki J, "Dual alpha (2)-adrenergic agonist and alpha (1)-adrenergic antagonist actions of dexmedetomidine on human isolated endothelium-denuded gastroepiploic arteries", Anesth Analg, 94, pp.1434~1440 (2002)
- Motulsky HJ, "Interaction of verapamil and other calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors", Circ Res, 52, pp.226~231 (1983)
- Kim HJ, "DIRECT EFFECT OF DEXMEDETOMIDINE ON RAT ISOLATED AORTA INVOLVES ENDOTHELIAL NITRIC OXIDE SYNTHESIS AND ACTIVATION OF THE LIPOXYGENASE PATHWAY", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 36(0), pp.406~412 (2009), Blackwell Science Asia
- Vanhoutte PM, "Calcium-entry blockers, vascular smooth muscle and systemic hypertension", Am J Cardiol, 55, pp.17B~23B (1985)
- Cussac D, "alpha 2B-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation", J Biol Chem, 277, pp.19882~19888 (2002)
- Shah S, "Severe hypertension and bradycardia after dexmedetomidine for radiology sedation in a patient with acute transverse myelitis", Paediatr Anaesth, 18, pp.681~682 (2008)
- Zub D, "Preliminary experience with oral dexmedetomidine for procedural and anesthetic premedication", Paediatr Anaesth, 15, pp.932~938 (2005)
- Sakurai Y, "Miyao H. Buccal administration of dexmedetomidine as a preanesthetic in children", J Anesth, 24, pp.49~53 (2010)
- Ebert TJ, "The effects of increasing plasma concentrations of dexmedetomidine in humans", Anesthesiology, 93, pp.382~394 (2000)
- Joshi MS, "Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells", Proc Natl Acad Sci U S A, 104, pp.9982~9987 (2007)